CMI, while calling it a milestone, said the approval comes after the company received IDE approvals for Magic Touch SCB to treat coronary in-stent restenosis (ISR) in September 2022 and Magic Touch PTA to treat "below the knee" peripheral arterial diseases (PAD) in February 2022. Magic Touch SCB is used for the treatment of small vessel indication in the coronary arteries.
from medical-devices - Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/ibxgvUB
via IFTTT
No comments:
Post a Comment